research Tumor Suppressor Activity of ODC Antizyme in MEK-Driven Skin Tumorigenesis 37 citations, January 2006 in “Carcinogenesis” Antizyme slows skin tumor growth by reducing cell growth in mice.
research IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes 32 citations, December 2019 in “The Journal of clinical investigation/The journal of clinical investigation” A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
research The Risk of Dermatological Toxicities of Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma Patients: A Systematic Review and Meta-Analysis 9 citations, December 2018 in “Cutaneous and Ocular Toxicology” Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
research The Role of MEK and Antizyme in Keratinocyte Stem Cell Expansion and Differentiation 1 citations, April 2012 in “Cancer Research” Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.
research Melanotic Pigmentation in Excisional Scar of Melanoma Patient Who Received BRAF and MEK Inhibitors 1 citations, August 2018 in “Journal of The American Academy of Dermatology” Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.